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ABSTRACT
The cutaneous malignant melanoma (CMM) incidence has been increasing in an exponential
manner in certain populations around the world for over 7 decades. To help illuminate the etiology,
we performed worldwide temporal (1955–2007) CMM incidence analysis by sex, age (0–14, 15–29,
30–49, 50–69, 70–85C), and skin type on 6 continents using data from the International Agency for
Research on Cancer. We observe an exponential increase in the CMM incidence over time and an
increase of about 2 orders of magnitude between age groups 0–14 and 15–29 exclusively in
European-ancestry populations around the world independent of skin type (I–III or III–IV). Other
populations like the Chinese (III-IV) had much lower CMM incidences that either remained stable or
temporally decreased but did not display a dramatic increase between the youngest age groups.
The dramatic increase in the incidence between the youngest age groups found only in European-
ancestry populations suggests one of the most important risk factors for CMM may be developing
androgenic hair, the occurrence of which appears to correlate with the distribution of CMM over
male and female body sites. Besides that potential new risk factor, the increasing CMM incidence
with increasing age, known not to be from cumulative UV doses, may be associated with age-
related changes to skin, i.e., thinning epidermis causing lower vitamin D3 levels, and hair, i.e.,
whitening from higher reactive oxygen species. The temporal exponential increasing CMM
incidence in European-ancestry populations may be due to Human Papilloma Virus infection of
follicular hair melanocytes, found in CMM biopsies.
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Introduction
The incidence of cutaneous malignant melanoma
(CMM) has been increasing in an exponential manner
for over 7 decades in certain indoor-working popula-
tions around the world.1-3 This increasing trend in
CMM incidence over time has been attributed to a
variety of risk factors: increasing terrestrial UVB radi-
ation (290–315 nm) from ozone depletion increasing
personal doses; increasing exposures to more body
sites (less clothing and smaller swimsuits like bikinis)
to erythemally-weighted UV radiation (UVR; 290–
400 nm), which is primarily UVB radiation;4 increas-
ing tanning behaviors using the UVR from tanning
devices or the sun during vacation holidays; increasing
changes in diagnostic criteria and surveillance;
increasing intermittent outdoor UVB exposures
thought to increase the occurrence of sunburns.
These are popular explanations for the increasing
trend in CMM over time; however, if true, they
would create several paradoxes. The most intrigu-
ing paradox concerns UVR exposure. For example,
higher doses from increasing terrestrial UVB radia-
tion due to decreasing ozone levels cannot explain
the increasing trends of CMM over time because
atmospheric ozone levels stabilized during the
1990s.5 More importantly, higher UVB doses can-
not explain these increasing CMM incidence trends
because outdoor workers get 3–10 times the annual
UVB doses that indoor workers get,6 yet they have
lower incidences of CMM than indoor workers
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have.7 Those ﬁndings also show cumulative UVB
doses cannot be responsible for the higher CMM
incidences observed with advancing age, so that
another explanation is needed. Increasing body sur-
face area exposure to UVB radiation does not
explain this increasing trend in CMM because
small bathing suits like bikinis were available since
the 1960s so that people have been exposing as
much of their surface body area as possible for
over 5 decades. Moreover, epidemiology studies
show that unlike non-melanoma skin cancer, which
primarily occurs on chronically exposed body
sites,8 CMM primarily occurs on intermittently
exposed body sites.9 Paradoxically, Fitzpatrick skin
type I-III10 Europeans actually displayed a signiﬁ-
cant correlation between increasing incidences of
CMM and decreasing UVB doses over time (p <
10¡6), most notably after 1960.2 Increasing tanning
behavior also does not explain this trend because,
along with all the observations already mentioned,
higher UVB exposures in the south steadily
decreased CMM while lower UVB exposures in the
north steadily increased CMM in the adolescent
population of the United States (US) from 1988 to
2009.11 Tanning indoors using devices along with
tanning outdoors using the sun during holiday
vacations to lower latitudes have also been blamed
for the temporal increases; however, CMM has
been gradually increasing in an exponential manner
since 1936 with no change in the slope of the
trendline throughout the time course (1936–
2000),1,3 which would be expected to occur some-
time after 1960 if tanning signiﬁcantly contributed
toward the risk.2 Although not a paradox, changes
in diagnostic criteria over time was also not con-
nected to the increasing incidence of CMM because
several countries around the world (Australia,
France, Italy, New Zealand, Norway, Sweden, the
United Kingdom, the US, and the Union of Soviet
Socialist Republics) were all found to have similar
histological diagnostic criteria in 1930, 1955, and
1980.12 Besides, it is not possible for all the physi-
cians around the world to gradually change their
CMM diagnostic criteria so that an exponential
increase would occur for over 6 decades with no
change in the trendline slope. Thus, scientists can-
not explain the exponential temporal increase in
CMM by increasing UVB doses, increasing body
sites exposed, increasing tanning indoors or
outdoors, or increasing changes in diagnostic crite-
ria. The remaining risk factor is intermittent sun
exposures.
Intermittent sun exposures were identiﬁed by epi-
demiology studies as the major risk factor associated
with initiating CMM and the consensus was that it
was due to intense UVB-induced sunburns, especially
during childhood, and that this somehow caused
CMM to increase over time. This belief created yet
another paradox for several reasons. First, sunscreens
with primarily UVB protection or with both UVB and
UVA (316–400 nm) protection and with increasing
sun protection factors have not reduced the incidence
of CMM since their creation over 5 decades ago. Sec-
ond, animal studies revealed sunscreens did not
reduce the growth of melanoma13 and, counter intui-
tively, higher UVB doses including sunburn doses,
actually gave decreasing numbers of animals with mel-
anomas.14 Third, human studies conﬁrmed sunscreens
only prevent sunburns not CMM15 and some epide-
miology studies actually found sunscreens increased
the risk for getting CMM in a dose-dependent man-
ner.16 Fourth, the most sun-sensitive individuals are
albinos who get severe sunburns and have numerous,
early onset non-melanoma skin cancers, but they
rarely get melanoma although they have the same
number of melanocytes as pigmented people.17 Note
that almost all epidemiology studies that concluded
intermittent sun exposures causing sunburns is a risk
factor for CMM did not include questions concerning
sun protective measures like avoidance behavior and
sunscreen use (see examples in reference 7), which
probably confounded the ﬁndings because fair-
skinned, sun-sensitive individuals are more prone to
protect themselves (see overview of studies in refer-
ence 18). Finally, the International Agency for
Research on Cancer (IARC) published an ofﬁcial
report concluding sunscreens do not protect against
getting CMM.19 Thus, the role of UVB-induced sun-
burns is questionable in human CMM, while the role
of UVA3 and visible light20 exposures have not been
fully elucidated.
The epidemiology studies that appeared to display
correlations between sunburns and CMM may actually
reﬂect the sun-sensitive individual’s reluctance to go out-
doors and be exposed to the burning UVB rays because
they harbor painful childhood sunburn memories. This
idea originated with epidemiology studies that found
people’s perception of having a tendency to sunburn,
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rather than the actual number of sunburns, along with
normally being untanned were risk factors associated
with CMM.21,22 Support for this idea came from a recent
well-documented epidemiology study that revealed the
risk for CMM was greatest in melanocortin-1-receptor
variant individuals with protective phenotypes who got
limited sun exposures, like those who tanned well after
repeated sun exposures (odds ratio, OR 2.4; 95% CI, 1.6–
3.6), had dark hair (OR 2.4; 95% CI 1.5–3.6), or had dark
eyes (OR 3.2; 95% CI 1.8–5.9), and the same risk pattern
was observed for persons who did not freckle, tanned
after their ﬁrst exposure to strong summer sun, reported
little or average recreational or occupational sun expo-
sure, or who reported no sun burning events compared
to controls; meta-analysis of published studies supported
those ﬁndings.23 In fact, increased childhood sun expo-
sures from outdoor activities were shown to be protective
against CMM yielding a lower risk24 while sun exposures
in adulthood or occupational exposures were not related
to the risk.25 Moreover, outdoor workers with lower inci-
dences of CMM actually get numerous sunburns every
year (reviewed in reference 26). Thus, the belief that
CMM is caused by sunburns at any age needs to be
reevaluated because it also created a paradox.
In order to help illuminate our understanding on
the etiology of CMM and possibly resolve some of
these apparent paradoxes, we extended our earlier
CMM studies1-3 to examine the role of age and skin
type. To do this we analyzed males and females in
5 age groups (0–14, 15–29, 30–49, 50–69, 70–85C yr.)
with Fitzpatrick skin types I-VI10 in 57 countries on 6
continents around the world from 1955 to 2007.
Materials and methods
Analysis of CMM incidence by sex, age, and skin type
over time (1955–2007)
We analyzed the age-standardized CMM (ICD-10,
C43) incidence rates (ASR) per 100,000 world standard
population at 5-year interval midpoints over time from
1955 to 2007 for males and females in 5 age groups (0–
14, 15–29, 30–49, 50–69, 70–85C) with Fitzpatrick
skin types I-III, III-IV, IV-V, and IV-VI.10 White, non-
Hispanic white or Caucasian skin is primarily repre-
sented by Fitzpatrick skin type I-III; Asian, Latino, His-
panic, and Polynesian skin is primarily represented by
Fitzpatrick skin type III-IV; brown to black or African
American skin is primarily represented by Fitzpatrick
skin type IV-VI;27 eastern Indian skin is primarily
represented by Fitzpatrick skin type IV-V;28 Mediterra-
nean, olive tone skin is primarily represented by Fitzpa-
trick skin type III-IV.29 One possible limitation to this
study is that a Fitzpatrick skin type for the primary
population of each country had to be assigned if the
IARC data did not segregate the populations by skin
type, e.g., white, non-Hispanic white, non-Maori,
Maori, or black (African-American).We used data des-
ignated as white, other white, or non-Hispanic white
for Fitzpatrick skin type I-III whenever available.
We used the national data or aggregated the regional
population-based cancer registry data to obtain a national
average from Cancer Incidence in Five Continents (CI5)
Volume I to X.30 For example, in Europe we aggregated
the regional registries for CMM incidences in Austria,
Belgium, England, France, Germany, Hungary, Poland,
Romania, Scotland, Switzerland, and The Netherlands to
estimate national incidence trends. Note that Denmark
began collecting data in 1953while all the other European
countries began collecting data after 1955 so we excluded
the 1953 data set. Iceland began collecting data in 1955
but their CMM incidence for the year 1960 actually
included the years 1955 to 1963. We included and ana-
lyzed all available data for each country around the world
whenever it began collecting data until 2007, but note
that some countries did not collect data during certain
time intervals between 1955 and 2007. In South America,
after regional aggregation, we averaged the CMM inci-
dence data of 6 countries: Argentina, Brazil, Chile,
Columbia, Ecuador and Uruguay. In Africa, after
regional aggregation, we averaged the CMM incidence
data for 8 countries: Egypt, Libya, Algeria, Uganda,
Malawi, Zimbabwe, South Africa, and Tunisia.
We analyzed 57 countries in total; the data shown
here is for Australia, the US (white, other white, or
non-Hispanic white), Europe (24 countries average
shown), China, South America (6 countries average
shown), Spain, Italy, Israel, New Zealand (Maoris),
India, Africa (8 countries average shown), and the US
African-American blacks. The data for the countries
analyzed but not shown here are New Zealand (non-
Maori whites), Canada, Japan, Cuba, Cyprus, Korea,
Kuwait, Malta, Philippines, Portugal, and Thailand.
The speciﬁc inclusion criterion was the availability
of at least 9 consecutive years of data. The editorial
process for quality control involves a detailed assess-
ment of the validity, completeness, and comparability
of the incidence data, the details of which are provided
online (http://ci5.iarc.fr/CI5I-X/old/vol10/I_08.pdf).
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This CMM data includes all tumor stages, thicknesses,
histological subtypes, and body site locations. IARC
data was obtained by the governments over the course
of decades having consistent criteria. The data is more
extensive than other databases because it covers a lon-
ger period of time (before 1975) and contains almost
all the countries of the world, not just the US, using
the same inclusion/exclusion criteria.
Skin type I-III continents and countries: Australia, US,
and Europe
On the Australian continent, we analyzed all the available
data for skin type I-III populations in each territory: Capi-
tal Territory (35.3N),New SouthWales (32.2N),North-
ern Territory (20N), Queensland (23N), South (30N),
Tasmania (42N), Victoria (37N), andWestern (26N).
InNewZealand (40.9N), we analyzed all the available
data for skin type I-III populations separately from the
native PolynesianMaori’s with skin types III-V.
On the North American continent in the US, we
analyzed skin type I-III populations separately
from skin types IV-VI for all states with available
data, but excluded Hawaii along with Alaska
because they did not segregate their skin type pop-
ulations for many years. The state’s populations
analyzed by sex and age for skin type I-III over
time or UVR dose in the US were: Hawaii
(21.31N), Florida (27.8N), Louisiana (30.7N),
Texas (30.9N), Mississippi (32.6N), Alabama
(33N), Georgia (33.3N), Arizona (33.4N), South
Carolina (34N), New Mexico (34.6N), Arkansas
(35.1N), California (35.5N), North Carolina
(35.6N), Oklahoma (35.6N), Tennessee (35.8N),
Virginia (37.8N), Kentucky (37.8N), Missouri
(38.4N). West Virginia (38.8N), Delaware
(39.4N), Colorado (39.5N), Indiana (40.2N),
New Jersey (40.4N), Utah (40.4N), Pennsylvania
(40.5N), Ohio (40.5N), Nebraska (41.2N), Illi-
nois (41.3N), Connecticut (41.5N), New York
State (41.5N; excluding New York City due to
skin type mix), Rhode Island (41.8N), Iowa
(41.9N), Massachusetts (42.3N), Wyoming
(42.7N), Michigan (42.9N), Wisconsin (43.7N),
South Dakota (44.1N), Vermont (44.1N), Idaho
(44.2N, only skin type I-III), Maine (44.3N), Ore-
gon (44.7N), Montana (46.8N), Washington State
(47.3N), and North Dakota (47.4N). We also
separately analyzed the native Hawaiians with pri-
marily skin types III-IV residing in Hawaii.
On the North American continent in Canada
(56.1N), we analyzed all the available data for skin type
I-III populations in each territory: Alberta, British
Columbia, Manitoba, New Brunswick, Newfoundland,
Northwest Territories, Nova Scotia, Ontario, Prince
Edward Island, andQuebec.
On the European continent, we separately analyzed
countries with darker skin type III-IV from those having
primarily lighter skin type I-III populations: Romania
(46N), Slovenia (46N), Switzerland (47N), France
(47N), Hungary (48N), Austria (48N), Slovakia
(49N), Czech (50N), Poland (51N), Germany (51N),
Belgium (51N), The Netherlands (52N), England
(52N), Ireland (53N), Belarus (54N), Lithuania
(55N), Denmark (56N), Scotland (57N), Latvia
(57N), Estonia (59N), Sweden (62N), Iceland (63N),
Norway (64N), and Finland (65N).
Skin type III-IV in countries and continents: China,
Japan, Spain, and South America
On the Asian continent in China, we analyzed skin type
III-IV populations in Beijing (39.9N), Cixian (36.4N),
Haining County (30.5N), Hong Kong (22.3N),
Jiashan (30.8N), Macao (22.2N), Nangang District,
HarbinCity (45.7N),QidongCounty (26.8N), Shang-
hai (31.2N), Wuhan (30.6N), Yangcheng County
(35.5N), Yanting County (31.2N), and Zhongshan
(22.5N).
In Japan, we analyzed skin type III-IV populations in
Aichi Prefecture (38.2N), Fukui Prefecture (37.5N),
Hiroshima 36N), Miyagi Prefecture (35N), Nagasaki
(34.7N), Niigata Prefecture (34.3N), Osaka Prefecture
(33.2N), and Saga Prefecture (32.8N).
On the European continent in Spain (40.5N), we ana-
lyzed skin type III-IV Spanish populations in Albacete,
Asturias, Basque Country, Canary Islands, Ciudad Real,
Cuenca, Girona, Granada, La Rioja, Mallorca, Murcia,
Navarra, and Tarragona.
On the continent of South America, we analyzed
skin type III-IV populations in 6 countries: Argentina
(Bahia Blanca 38.7S, Cordoba 31.4S, Mendoza
32.9S, Tierra del Fuego 54S), Brazil (Aracaju 10.9S,
Belo Horizonte 19.9S, Cuiaba 15.6S, Fortaleza 3.7S,
Goiania 16.7S, Sao Paulo 23.6S), Chile (Biobio Prov-
ince 37.4S, Region of Antofagasta 23.7S, Valdivia
39.8S), Columbia (Bucaramanga 7.1N, Cali 3.4N,
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Manizales 5.1N, Pasto 1.2N), Ecuador (Cuenca
2.9S, Quito 0.2S), and Uruguay (34.9S).
Skin type III-IV populations in Italy and Israel, skin
type IV-V in India, skin type IV-VI in the US, and skin
types III-VI in Africa
On the European continent in Italy, we analyzed the data
for skin type III-IV populations in Alto Adige (46.4N),
Biella Province (45.6N), Brescia Province (45.6N), Cat-
ania and Messina (37.5N), Catanzaro (38.9N), Ferrara
(44.8N), Florence (43.8N), Friuli-Venezia Giulia
(46.1N), Genoa (44.4N), Latina Province (41.5N),
Lombardy Como Province (45.8N), Lombardy Lecco
Province (45.9N), Lombardy Mantova Province
(45.2N), Milan (45.5N), Modena (44.7N), Naples
(40.9N), Nuoro (40.3N), Palerme (38.1N), Parma
Province (44.8N), Ragusa Province (36.9N), Reggio
Emilia Province (44.7N), Romagna (44.5N), Salerno
(40.7N), Sassari (40.7N), Sondrio (46.4N), South
Lombardy (45.7N), Syracuse Province (37.1N), Torino
(45.1N), Trapani (38N), Trento (46.1N), Umbria
(43N), Varese Province (45.8N), and Venetian Region
(45.4N).
In Israel (31.1N), we analyzed the data for their
skin type III-IV Jewish population.
In India, we analyzed skin type IV-V populations in
Bangalore (13N), Barshi (18.2N), Bhopal (23.3N),
Chennai (Madras,13N), Delhi (28.7N), Dindigul,
Ambillikai (10.4N), Karunagappally (9N), Mizoram
(23.4N), Mumbai (Bombay, 19N), Poona (18.5N),
Sikkim State (27.3N), and Trivandrum (8.5N).
On the North American continent in the US, we ana-
lyzed skin type IV-VI populations separately for all states
with available data. The state’s populations analyzed by
sex and age for type V-VI over time and UVR dose in the
US were: Florida (27.8N), Louisiana (30.7N), Texas
(30.9N), Alabama (33N), Georgia (33.3N), Arizona
(33.4N), South Carolina (34N), Arkansas (35.1N),
California (35.5N), North Carolina (35.6N), Oklahoma
(35.6N), Tennessee (35.8N), Virginia (37.8N), Mis-
souri (38.4N), Delaware (39.4N), Colorado (39.5N),
Indiana (40.2N), New Jersey (40.4N), Pennsylvania
(40.5N), Ohio (40.5N), Nebraska (41.2N), Illinois
(41.3N), Connecticut (41.5N), New York State
(41.5N; excluding New York City due to the mix of skin
types), Rhode Island (41.8N), Massachusetts (42.3N),
Michigan (42.9N), Wisconsin (43.7N), and Oregon
(44.7N).
On the African continent, we analyzed all the available
data for countries with skin type III-VI populations:
Egypt (Gharbiah; 26N), Libya (Benghazi; 32.1N),
Algeria (Setif Wilaya; 36.2N), Uganda (Kyadondo
County; 1.07N), Malawi (Blantyre; 15.8N), Zimbabwe
(Harare; 17.9N), South Africa (PROMEC; 30N), and
Tunisia (North; 34N).
Statistical analysis
For all the data, we conducted linear regression analysis
using Minitab 16.2.4 (Minitab Inc., State College, Penn-
sylvania) to assess the role of time in predicting log
(CMM) incidence rate in each age group studied and
consider p< 0.05 signiﬁcant. These predictions were also
used to create Figure 5, where estimated incidence at
2010 at each of the 5 studied age groups was plotted for
Australianmales and South Americanmales.
Results
We began by analyzing the CMM incidence of skin
type I-III populations in Australia (New Zealand,
results not shown), North America (in the US;
Canada, results not shown), and Europe and found
CMM increasing in an exponential manner over time
for both males and females older than 14 y. (Fig. 1 left,
middle, and right panels, respectively). Australian
females were the only exception displaying no trend
for ages 15–29 (p > 0.9, Figure 1 left lower panel).
Note that all of these European-ancestry populations
display a dramatic (about 2 log units) increase in the
incidence of CMM between the 2 youngest age groups,
i.e., 0–14 and 15–29.
In contrast to the skin type I-III populations around
the world, the skin type III-IV populations with yellow
skin tone have lower incidences and display either
somewhat stable or downward trends over time for
most age groups, except for the European-ancestry
population in Spain (Fig. 2). On the Asian continent,
the Chinese with skin type III-IV display decreasing
temporal trends and do not have a dramatic increase in
the CMM incidence between the 2 youngest age groups
(Fig. 2 left panels), similar to the Japanese, Korean, and
Thai populations (results not shown). Analysis of the
continent of South America with skin type III-IV pop-
ulations, reveals no increasing trend of CMM over time
or a dramatic increase in the incidence between the
youngest age groups for males but does show a slight
increasing trend for females and a noticeable increase
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in the incidence between the 2 youngest age groups,
similar to, but not as pronounced as the skin type I-III
population (Fig. 2 middle panels). The European-
ancestry population in Spain is the only skin type III-
IV population that exhibits an exponential increasing
trend over time and appears to have a dramatic
increase in the risk for CMM after age 14, similar to the
skin type I-III European-ancestry population (Fig. 2
right panels).
The European-ancestry Italian (Fig. 3 left panels)
and Israeli (Fig. 3 middle panels) skin type III-IV pop-
ulations with olive skin tone also have increasing
Figure 1. Age-standardized CMM cases per 100,000 people by year for males and females with Fitzpatrick skin type I–III.
Figure 2. Age-standardized CMM cases per 100,000 people by year for males and females with Fitzpatrick skin type III–IV.
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temporal CMM incidence trends for both males and
females over the age of 14 and also display the dra-
matic increase in the CMM incidence between the 2
youngest age groups. However, the native Maori Poly-
nesian populations with skin type III-IV residing in
New Zealand have CMM incidences that remained
primarily unchanged over time for all male and female
age groups (Fig. 3 right panels), similar to the native
Hawaiian Polynesian population in Hawaii with skin
type III-IV (results not shown). These Polynesian skin
type III-IV populations, unlike the Italian or Jewish
skin type III-IV populations, do not display this dra-
matic increase in the CMM incidence between the 2
youngest age groups.
The eastern Indian skin type IV-V (Fig. 4 left pan-
els) and the African skin types III-VI (Fig. 4 middle
Figure 3. Age-standardized CMM cases per 100,000 people by year for males and females with Fitzpatrick skin type III–IV and IV–V.
Figure 4. Age-standardized CMM cases per 100,000 people by year for males and females with Fitzpatrick skin type V–VI.
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panels) and US African-American (black) skin type
IV-VI populations (Fig. 4 right panels) also do not
have increasing temporal CMM incidence trends but
rather appear to either remain stable or decrease over
time depending on the age group. Note that these skin
type III-VI populations also do not display the dra-
matic increase in the incidence between the 2 youngest
age groups.
Curiously, regardless of skin type (I–IV) only the
European-ancestry populations display a dramatic
increase in the incidence of CMM between the 2
youngest age groups, i.e., 0–14 y. and 15–29 y., com-
pared with the other age groups that have gradual
increases. In Figure 5, we demonstrate the intensity
(about 2 log units) of this change in the CMM inci-
dence between the 2 youngest age groups using Aus-
tralian males as an example of European-ancestry and
contrast that result using South America males as an
example of all other populations that do not display
this dramatic increase.
Finally, we asked if the CMM increases in the inci-
dences of males and females of different ages were sig-
niﬁcant over time for the skin type I-III populations
and analyzed the US as an example (Table 1). The
trends over time were signiﬁcant for both males and
females in all age groups over 14.
Discussion
For the ﬁrst time, the CMM incidences over 5 decades
(1955–2007) have been analyzed for males and
females in all age groups (0–14, 15–29, 30–49, 50–69,
70–85C yr.) with all Fitzpatrick skin types (I-VI) in
57 countries on 6 continents around the world. Previ-
ous studies ignored the youngest age groups (either
below the age of 15 or 30), but we analyzed all age
groups to obtain more clues into the etiology of
CMM. We observe steady temporal exponential
increases of CMM incidence exclusively in European-
ancestry populations around the world regardless of
skin type, I-III (Fig. 1; and in New Zealand and Can-
ada, results not shown), III-IV with yellow skin tone
(only in Spain, Figure 2 right panels) and III-IV with
olive skin tone (both in Italy, Figure 3 left panels, and
in Israel, Figure 3 middle panels). All other non-Euro-
pean-ancestry skin type III-VI populations around the
world like the Chinese or South Americans, or
the skin type IV-V populations in eastern Indian,
or the skin type III-VI populations in Africa or the
skin type IV-VI in the US have much lower CMM
incidences that are either stable or slightly decrease
over time (Figs. 2–4). Using the US as an example of
the European-ancestry skin type I-III populations, we
calculated p values that show signiﬁcant trends over
time in the CMM incidence for all age groups over
14 y. (Table 1). Surprisingly, we discovered a dramatic
increase in the CMM incidence exists between the
2 youngest age groups, i.e., 0–14 and 15–29 yrs., in
only the European-ancestry populations regardless of
skin type (I-III or III-IV). We analyzed this dramatic
increase in the CMM incidence by comparing Austra-
lian males with South American males to represent
each scenario (i.e., European-ancestry versus non-
European-ancestry) and found about a 2-unit log
increase, or factor of about 100, exists only between
the youngest Australian age groups (Fig. 5 top curve).
Note here that the next 2-unit log increase requires
the remainder of a person’s entire lifetime to achieve.
In contrast, the non-European-ancestry populations
represented by the males in South America display a
gradual increase in the CMM incidence for all the age
groups (Fig. 5 bottom line).
Figure 5. Vertical y-axis is the estimated log(CMM) at 2010 for
either Australian () or South American (&) males and the hori-
zontal x-axis has the 5 age groups in increasing order, i.e., age
group 1 is the youngest 0–14 y. and age group 5 is the oldest,
70–85C.
Table 1. Statistical analysis of CMM over time (1955–2007) for US
males and females. Signiﬁcance of regression for log(CMM inci-
dence) versus time.
Age Group Male R2 Female R2 Male p values Female p values
0–14 0.01 0.02 0.78 0.73
15–29 0.77 0.93 1.0 £ 10¡3 7.6 £ 10¡6
30–49 0.68 0.94 3.0 £ 10¡3 3.9 £ 10¡6
50–69 0.98 0.99 4.1 £ 10¡8 2.9 £ 10¡9
70–85C 0.94 0.98 2.0 £ 10¡6 4.1 £ 10¡8
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What might explain the exponential increase in the
incidence of CMM over the last 5 decades? One possi-
ble explanation is a contagious disease, e.g., viral infec-
tion. One viral infection found in CMM that has been
increasing at an exponential rate in recent decades in
at least Europe and the US is the Human Papilloma
Virus (HPV).31,32 Clinicians ﬁnd both the cutaneous b
HPV strains (e.g., HPV-38) and the high-risk mucosal
a HPV strains (HPV-16 and 18) in acquired dysplastic
nevi and in over half the CMM biopsies.33,34 The high-
risk mucosal a HPV strains immortalize melanocytes
via their E6 and E7 proteins that inactivate 2 major
apoptotic pathways (p53 and Bak, respectively), set-
ting the scenario for expedient transformation.35 In
addition to HPV infection increasing exponentially
over the last few decades, vitamin D levels have
decreased dramatically from 1965 to 2010, as demon-
strated by the inversely related parathyroid hormone
levels that increased almost 10-fold during that
period.36 Vitamin D3 levels have decreased over time
due to less UVB exposure because people have been
wearing more protective sunscreens37 and have been
spending more time indoors, further decreasing their
exposure to UVB radiation while increasing their
exposure to UVA radiation passing through glass win-
dows in ofﬁce buildings and cars.3 Only UVA radia-
tion can pass through glass, but rather than making
vitamin D3 like UVB radiation doses,
38 UVA only
destroys it. The importance of vitamin D in CMM is
demonstrated by the prediagnostic deﬁcient and insuf-
ﬁcient blood levels of melanoma patients39 and by the
fact that indoor workers have about half the vitamin
D levels that outdoor workers have40 and have a sig-
niﬁcantly higher risk (OR of about 1.6) for getting
CMM than outdoor workers have (OR of about 0.8).7
Mechanistically, vitamin D3 can induce apoptotic cell
death of melanoma cells41 and enables their killing by
activated T cells.42 Interestingly, upon integration into
the host genome, HPV can delete a large section of the
DNA on chromosome 12q (12q13–15)43 where the
vitamin D receptor is located (12q13.11) removing yet
another major apoptotic cell death pathway. Curi-
ously, this section of the chromosome also includes
CDK4, MDM2 and SAS and is found as an amplicon
in many soft tissue tumors.44 In addition, the seasonal
ﬂuctuations in vitamin D levels together with HPV
infection expediting transformation may explain the
noted seasonality of CMM diagnosis.45 A recent study
found the OR of vaccine-type HPV infections were
increased to 2.19 for women who had insufﬁcient
(20–29 ng/ml) or deﬁcient (12–19 ng/ml) vitamin D
levels and increased to an OR of 2.9 for women with
severe vitamin D deﬁciency (<12 ng/ml).46 HPV
infection occurs when vitamin D levels are low during
the winter and spring months and promotion toward
the cancerous state occurs during the summer months
when UVB radiation is maximized47 presumably
because it causes immune suppression via soluble fac-
tors produced by skin cells. In an earlier study, we
found a signiﬁcant correlation between cervical and
pharyngeal cancers - known to be caused by HPV
infection - with increasing personal UVB dose (or
decreasing latitude) in the US supporting a role for
immunosuppressive soluble factors such as IL-10.48 In
support of a combined role for low vitamin D levels
and HPV infection, we found the incidence of CMM
increased signiﬁcantly with lower personal UVB dose
(or increasing latitude) only after 1960 in Europe.49 If
people wear sunscreens during the summer, they will
make little vitamin D3
37 and still produce immuno-
suppressive soluble factors from the UVA radiation
increasing the risk for HPV-related cancers. Thus, it
appears that deﬁcient and even insufﬁcient levels of
vitamin D along with immune suppression increases
the likelihood of having a prevalent HPV infection,
which may increase the risk for getting CMM.
What might explain the 2 orders of magnitude dra-
matic increase in the CMM incidence between the 2
youngest age groups (0–14 and 15–29) that occurs
exclusively in the European-ancestry populations
around the world? The common explanation of lighter
skin color does not explain this dramatic increase
because, besides our ﬁndings, others found no signiﬁ-
cant difference exists in the CMM incidence between
skin type I/II and III/IV Europeans (p D 0.79)50 or
Americans.23 One plausible explanation is the hor-
monal changes that occur during puberty associated
with growing androgenic body hair, the distribution of
which51 aligns well with the distribution of CMM.9,52
Both androgenic body hair and CMM occur most fre-
quently on the face, neck, and torso of males and the
lower limbs of females. In addition to CMM and
nevi,32,33 HPV is also found in hair follicles that are res-
ervoirs for persistent HPV infection3 because they are
immune-privileged sites.54 Androgenic body hair may
explain the dramatic increase in CMM incidence
observed exclusively in people of European-ancestry
over the age of 14 regardless of skin type because they
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apparently have the most androgenic body hair of all
the worlds’ populations. For ages 14 and under, vellus
hair appears to play a role in CMM.55
But why does the CMM incidence continue to
increase with advancing age if it is not dependent on
the cumulative UVB dose? One possible explanation
is the aging process itself, which results in several
body changes including increasing amounts of reac-
tive oxygen species producing more oxidative DNA
mutations and white hair along with thinning of the
epidermis of skin producing less vitamin D3.
56
Human white hair may be important in the etiology
of CMM for 2 reasons; it represents increased pro-
duction of reactive oxygen species57 and it may allow
transmission of UV down the hair shaft delivering
higher doses of UVA along with some UVB to the
melanocytes in the follicular bulge.58 Although white
hair does not technically act like a ﬁber optic cable, it
does allow transmission of UVA and UVB down the
hair shaft (Fig. 3 in reference 58), which may explain
why people over the age of 50 get CMM on body
sites that received continual sun exposure.52 People
of European-ancestry with red hair may be at the
highest risk for getting CMM because their hair
begins to turn white at the youngest age (in their
20s) compared with other skin type I-III people who
have darker hair that begins to turn gray in their 30s;
people of Asian-ancestry with brown/black hair begin
to turn gray in their late 30s; people of African-
ancestry with brown/black hair begin to turn gray in
their 40s.57 More importantly, redheads change
directly from red to white hair without passing
through the gray hair stage, as all other people do.
Some evidence for the idea that white hair allows
transmission of UVA (and visible light) and UVB to
irradiate follicular melanocytes can be found in the
gray horse model that has protective black skin and
only gets melanoma after its gray hair turns white.59
Conclusions
The incidence of CMM has been gradually increasing
in an exponential manner over the past several decades
and increases dramatically after the age of 14, implicat-
ing androgenic melanocytes may be involved, but only
in people of European-ancestry. In addition, CMM
may develop through 2 major pathways; one observed
in the younger populations (<50 ) that may be primar-
ily affected by vitamin D3 and may be UVA and Visible
light-driven through skin to follicular vellus and andro-
genic melanocytes and the other observed in the older
populations (>50 ) that may be partially affected by
vitamin D3 and may be UVA&UVB-driven through
thinner skin and possibly through white hair to andro-
genic follicular melanocytes. Note that both pathways
may be accelerated by HPV infection. If our hypothesis
is true, we would expect to see a decrease in the inci-
dence of CMM over the next few decades if everyone
gets the HPV vaccination.
Abbreviations
CMM cutaneous malignant melanoma
HPV Human Papilloma Virus
OR odds ratio
US United States
UVR Ultraviolet Radiation (290–400 nm)
UVA Ultraviolet-A (316–400 nm)
UVB Ultraviolet-B (290–315 nm)
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